The U.S. Supreme Court’s 2019 decision in Merck Sharp & Dohme, Inc. v. Albrecht, 139 S.Ct. 1668 (2019), discussed... addressed impossibility preemption in label change lawsuits. In Albrecht, the Supreme Court purported to...more
3/23/2020
/ Food and Drug Administration (FDA) ,
Generic Drugs ,
GlaxoSmithKline ,
Labeling ,
Merck ,
Merck Sharp & Dohme Corp. v. Albrecht ,
Pharmaceutical Industry ,
PLIVA v Mensing ,
Preemption ,
Product Labels ,
SCOTUS ,
Wyeth